New radioactive drug takes aim at Hard-to-Treat prostate cancer
NCT ID NCT05570994
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new radioactive drug, 177Lu-HTK03170, designed to seek out and destroy prostate cancer cells that have spread. It is for men with metastatic castration-resistant prostate cancer whose disease has worsened after other treatments. The trial will first find a safe dose, then measure how well it shrinks tumors and controls the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-HTK03170 (a radioactive drug that targets prostate cancer cells)
What this could lead to
If successful, this could provide a new, personalized radiation treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 50 participants, so the treatment may not prove effective or safe in larger groups. Potential side effects from radiation exposure are unknown at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer
Vancouver, British Columbia, V5Z 4E6, Canada